Patterns of remission and relapse in obsessive-compulsive disorder: a 2-year prospective study

J Clin Psychiatry. 1999 May;60(5):346-51; quiz 352. doi: 10.4088/jcp.v60n0514.

Abstract

Objective: This study examined the course of illness in patients with obsessive-compulsive disorder (OCD) over a 2-year period.

Method: Sixty-six patients with a primary diagnosis of DSM-III-R OCD were followed prospectively for 2 years. Baseline information was collected on demographic characteristics, Axis I and II diagnoses, and severity of OCD symptoms. Follow-up measures obtained at 3, 6, 12, and 24 months after baseline assessment included information on symptomatic and diagnostic status as well as behavioral and somatic treatments received.

Results: The probability of full remission from OCD over the 2-year period was 12%. The probability of partial remission was 47%. After achieving remission from OCD, the probability of relapse was 48%. No factors were identified that significantly predicted full or partial remission. Seventy-seven percent (N = 51) of the subjects received a serotonin reuptake inhibitor (SRI) for > or =12 weeks, and 68% (N = 45) received medium-to-high doses of SRIs for > or =12 weeks. Only 18% received a full trial of behavior therapy.

Conclusion: Despite exposure to at least 1 adequate trial of an SRI, the likelihood of full remission of OCD in this study was low. Results of this study also suggest that behavior therapy may be under-utilized.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Age of Onset
  • Behavior Therapy
  • Cohort Studies
  • Comorbidity
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Mental Disorders / epidemiology
  • Obsessive-Compulsive Disorder / diagnosis*
  • Obsessive-Compulsive Disorder / epidemiology
  • Obsessive-Compulsive Disorder / therapy
  • Probability
  • Prospective Studies
  • Psychiatric Status Rating Scales / statistics & numerical data
  • Recurrence
  • Selective Serotonin Reuptake Inhibitors / therapeutic use
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Serotonin Uptake Inhibitors